# Hereditary Angioedema FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/hereditary-angioedema

> 2 upcoming FDA catalysts in hereditary Angioedema: DAWNZERA™ (donidalorsen, IONS) on December 2026 (primary completion); DAWNZERA™ (donidalorsen, IONS) on Dec 2026 to Mar 2027 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 10, 2026 | [NTLA-2002 primary completion](https://sec-api.dev/pdufa/ntla-2002) | NTLA | Hereditary Angioedema | completed | "NCT06634420 (HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-10 (ACTUAL); Lead Sponsor Intellia Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06634420)) |
| December 2026 | [DAWNZERA™ (donidalorsen) primary completion](https://sec-api.dev/pdufa/donidalorsen) | IONS | Hereditary Angioedema | scheduled | "NCT05392114 (A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Ionis Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05392114)) |
| Dec 2026 to Mar 2027 | [DAWNZERA™ (donidalorsen) topline data readout](https://sec-api.dev/pdufa/donidalorsen) | IONS | Hereditary Angioedema | scheduled | "NCT05392114 (A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Ionis Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05392114)) |

## Drugs

- [NTLA-2002](https://sec-api.dev/pdufa/ntla-2002) (NTLA)
- [DAWNZERA™ (donidalorsen)](https://sec-api.dev/pdufa/donidalorsen) (IONS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/hereditary-angioedema.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Hereditary Angioedema FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/hereditary-angioedema

```bibtex
@misc{secapidev_indications_hereditary_angioedema_20261116,
  title        = {Hereditary Angioedema FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/hereditary-angioedema}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_hereditary_angioedema_20261116","title":"Hereditary Angioedema FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/hereditary-angioedema","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
